Kirollos S. Hanna, PharmD, BCPS, BCOP

home / authors / kirollos-s-hanna-pharmd-bcps-bcop

Articles

NCCN Guidelines: Rapid Change in CLL Treatment Concepts

Kirollos S. Hanna, PharmD, BCPS, BCOP;Taylor M. Weis, PharmD, BCOP

July 12th 2021

Taylor M. Weis, PharmD, BCOP, discusses NCCN guidelines for first-line therapy as well as the rationale behind the rapid change in treatment concepts for CLL.

CLL: Treatment Paradigm Shifts and Impact on Outcomes

Kirollos S. Hanna, PharmD, BCPS, BCOP;Taylor M. Weis, PharmD, BCOP

June 30th 2021

Kirollos S. Hanna, PharmD, BCPS, BCOP, provides an overview of the shifts in treatments, trends, and outcomes seen over the past decade in CLL.

Published: January 18th 2016 | Updated: October 18th 2024

10 Pharmacy Quotes That Will Make You Rethink the Profession

Published: September 22nd 2015 | Updated: October 14th 2024

Gabapentin Differs From Pregabalin in Several Key Ways

Semaglutide injecting pen on a white background, macro. Needle macro - Image credit: artmim | stock.adobe.com

Published: October 17th 2024 | Updated: October 23rd 2024

Concerns Linger About GLP-1 Agonists Despite Their Popularity

Vial with pneumococcal disease vaccine and syringe for injection.

Published: October 21st 2024 | Updated: October 23rd 2024

Pneumococcal 21-Valent Conjugate Vaccine Generates Positive Response in Adults at Increased Risk of Disease

Myasthenia Gravis disease blood test in doctor hand

Published: October 21st 2024 | Updated: October 23rd 2024

Myasthenia Gravis Negatively Impacts Patients and Care Partners Through Clinical, Financial Burdens

FDA Approval, Stelara, Biosimilar | Image Credit: Calin - stock.adobe.com

Published: October 1st 2024 | Updated: October 23rd 2024

FDA Approves Ustekinumab-Aauz as Biosimilar for Stelara

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Kirollos S. Hanna, PharmD, BCPS, BCOP

Articles

Latest Updated Articles